Literature DB >> 19922436

Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link.

M Scully1, J Brown, R Patel, V McDonald, C J Brown, S Machin.   

Abstract

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare, acute, life-threatening disorder, associated with a deficiency in ADAMTS 13. The majority of acute, idiopathic, adult TTP cases are associated with anti-ADAMTS 13 IgG antibodies. However, the factor(s) precipitating an acute TTP episode are not always obvious; indeed, a multifactorial etiology is likely. OBJECTIVES AND METHODS: DNA was used for human leukocyte antigen (HLA) class II typing, using polymerase chain reaction (PCR)-sequence-specific primer and PCR-sequence-specific oligonucleotide probe to methodology to investigate 50 European acquired idiopathic TTP cases.
RESULTS: There was an increase in the frequency of HLA-DQB1*0301 (HLA-DQ7) in patients with TTP as compared with controls [58.0% vs. 34.5% (P=0.048)]. The frequencies of HLA-DRB1*11 and HLA-DRB3* were also significantly increased in TTP patients as compared with controls [44.0% vs. 12.0% (P=0.0024) and 84.0% vs. 58.0% (P=0.024)], although it remains uncertain whether susceptibility is influenced by HLA-DQ or HLA-DR molecules or other genes in this haplotype. The frequencies of HLA-DRB1*04 and HLA-DRB4 (HLA-DR53) were significantly decreased in the patient group as compared with controls [10.0% vs. 35.0% and 26.0% vs. 61.5% (P=0.0096 and P=0.0024, respectively)], and may have a protective effect against the development of TTP.
CONCLUSION: Analysis identified HLA class II types associated with susceptibility to and a protective effect against the development of acute acquired TTP in European patients. This provides the first description of a genetic factor predicting the risk of developing acquired antibody-mediated TTP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922436     DOI: 10.1111/j.1538-7836.2009.03692.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

1.  Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  Flora Peyvandi; Roberta Palla; Luca A Lotta
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

Review 2.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

3.  Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases.

Authors:  Xinping Zhou; Xingnong Ye; Yanling Ren; Chen Mei; Liya Ma; Jiansong Huang; Weilai Xu; Juying Wei; Li Ye; Wenyuan Mai; Wenbin Qian; Haitao Meng; Jie Jin; Hongyan Tong
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

4.  The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages.

Authors:  Fabian C Verbij; Nicoletta Sorvillo; Paul H P Kaijen; Johana Hrdinova; Ivan Peyron; Rob Fijnheer; Anja Ten Brinke; Alexander B Meijer; Floris P J van Alphen; Timo K van den Berg; Jonas J H Graversen; Soren K Moestrup; Jan Voorberg
Journal:  Blood Adv       Date:  2017-01-16

5.  The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  K Balassa; H Andrikovics; P Remenyi; A Batai; A Bors; K P Kiss; A Szilvasi; K Rajczy; D Inotai; L Gopcsa; L Lengyel; A Barta; M Reti; A Tordai; T Masszi
Journal:  Bone Marrow Transplant       Date:  2015-07-06       Impact factor: 5.483

6.  A systematic review and meta-analysis of HLA class II associations in patients with IgG4 autoimmunity.

Authors:  Anja Panhuber; Giovanni Lamorte; Veronica Bruno; Hakan Cetin; Wolfgang Bauer; Romana Höftberger; Astrid C Erber; Florian Frommlet; Inga Koneczny
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

7.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Authors:  Evgeny Arons; Sharon Adams; David J Venzon; Ira Pastan; Robert J Kreitman
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

8.  The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Authors:  Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

9.  Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).

Authors:  Jason H Karnes; Christian M Shaffer; Robert Cronin; Lisa Bastarache; Silvana Gaudieri; Ian James; Rebecca Pavlos; Heidi E Steiner; Jonathan D Mosley; Simon Mallal; Joshua C Denny; Elizabeth J Phillips; Dan M Roden
Journal:  Pharmacotherapy       Date:  2017-09-04       Impact factor: 4.705

10.  Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.

Authors:  E Becerra; M A Scully; M J Leandro; E O Heelas; J-P Westwood; I De La Torre; G Cambridge
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.